Company analysis

Emerging Pharma
Big Pharma
Mid Pharma
Japan Pharma
Hot Topics
M&A Analysis

Text search

Sort by Random

Display 30 Products per page

Company Analysis: UCB

$3,000.00

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
January 25, 2021
Find out more
Immuno-Oncology Deal Trends, 2012–16

$2,995.00

Immuno-oncology is an emerging field in medicine that has the potential to radically change how cancer is treated.
April 19, 2017
Find out more
Orphan Drug Market Outlook to 2017

$3,000.00

Tumbling over the patent cliff, many Big Pharma companies are being forced to find new strategies for sustaining sales growth, wherever possible minimizing the risk of generic competition.
September 28, 2016
Find out more
Company Analysis: Johnson & Johnson

$3,000.00

PharmaVitae explores Johnson & Johnson’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: Merck KGaA

$3,000.00

PharmaVitae explores Merck KGaA’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2020
Find out more
Company Analysis: Regeneron

$3,000.00

PharmaVitae explores Regeneron’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: Alexion

$3,000.00

PharmaVitae explores Alexion’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Pharma-Payer Partnerships in Emerging Markets

$2,995.00

Payer partnerships are becoming widespread as emerging markets become wealthier, but access challenges remain. Partnerships with proven success include “strategic philanthropy,” patient access programs, tiered pricing, and service support models.
July 26, 2017
Find out more
Company Analysis: Sanofi

$3,000.00

PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Under the Radar Takeover Targets

$3,000.00

Following on from its M&A Outlook 2018 report, PharmaVitae highlights under the radar takeover targets that are potentially attractive to companies on the prowl for acquisitions.
July 20, 2018
Find out more
Big Pharma Outlook 2026

$2,700.00

Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2025.
June 29, 2017
Find out more
Company Analysis: Incyte

$3,000.00

PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *